Shares of Quest Diagnostics (NYSE: DGX) climbed 6.3% on Thursday after the medical testing giant boosted its full-year sales and profit forecast. 

Quest's revenue decreased by 10% year over year to $2.5 billion in the third quarter. The decline was driven by a 55% drop in the company's COVID-19 testing sales.

However, Quest's base business revenue, which excludes COVID testing, grew by 5%.

Continue reading

Source Fool.com